Publications by authors named "Laura Angelats"

Claim this Profile
B
Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study.
Javier García-Corbacho, Alberto Indacochea, Iván Victoria, Débora Moreno, Laura Angelats

Cancer Immunol Immunother· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unlocking the potential of engineered immune cell therapy for solid tumors.
Víctor Albarrán-Fernández, Laura Angelats, Julio Delgado, Alena Gros, Álvaro Urbano-Ispizua

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez Hernández, Tomás Pascual, Guillermo Villacampa, Laura Angelats

EBioMedicine· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
Irene Andreu-Saumell, Alba Rodriguez-Garcia, Vanessa Mühlgrabner, Marta Gimenez-Alejandre, Berta Marzal, Laura Angelats

Nat Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.
Lucía Gutiérrez-Chamorro, Eudald Felip, Eva Castellà, Vanessa Quiroga, Ifeanyi Jude Ezeonwumelu, Laura Angelats

Cell Oncol (Dordr)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis.
David Pesántez, Alberto Indacochea, Laura Angelats, Marianna Sirico, Iván Victoria

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
Javier García-Corbacho, Alberto Indacochea, Azucena E González Navarro, Iván Victoria, Débora Moreno, Laura Angelats

Cancer Immunol Immunother· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
Javier García-Corbacho, Alberto Indacochea, Azucena E González Navarro, Iván Victoria, Débora Moreno, Laura Angelats

Cancer Immunol Immunother· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, Tomás Pascual, Laia Paré, Laura Angelats

J Natl Cancer Inst· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis